clofazimine has been researched along with Carcinoma, Hepatocellular in 5 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The riminophenazine compound clofazimine has been shown to be a potent inhibitor of hepatocellular carcinoma (HCC) in vitro." | 9.09 | A phase II evaluation of clofazimine plus doxorubicin in advanced, unresectable primary hepatocellular carcinoma. ( Falkson, CI; Falkson, G, 1999) |
| "Thirty patients (26 males and four females) with unresectable (25) or metastatic (5) hepatocellular carcinoma received oral clofazimine 600 mg daily for two weeks, followed by 400 mg daily until progression or death." | 9.08 | A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma. ( Chasen, MR; Long, JE; Ruff, P; van Rensburg, CE, 1998) |
| "The riminophenazine compound clofazimine has been shown to be a potent inhibitor of hepatocellular carcinoma (HCC) in vitro." | 5.09 | A phase II evaluation of clofazimine plus doxorubicin in advanced, unresectable primary hepatocellular carcinoma. ( Falkson, CI; Falkson, G, 1999) |
| "Thirty patients (26 males and four females) with unresectable (25) or metastatic (5) hepatocellular carcinoma received oral clofazimine 600 mg daily for two weeks, followed by 400 mg daily until progression or death." | 5.08 | A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma. ( Chasen, MR; Long, JE; Ruff, P; van Rensburg, CE, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scagliola, A | 1 |
| Miluzio, A | 1 |
| Ventura, G | 1 |
| Oliveto, S | 1 |
| Cordiglieri, C | 1 |
| Manfrini, N | 1 |
| Cirino, D | 1 |
| Ricciardi, S | 1 |
| Valenti, L | 1 |
| Baselli, G | 1 |
| D'Ambrosio, R | 1 |
| Maggioni, M | 1 |
| Brina, D | 1 |
| Bresciani, A | 1 |
| Biffo, S | 1 |
| Pourgholami, MH | 1 |
| Lu, Y | 1 |
| Wang, L | 1 |
| Stephens, RW | 1 |
| Morris, DL | 1 |
| Wadee, AA | 1 |
| Paterson, A | 1 |
| Coplan, KA | 1 |
| Reddy, SG | 1 |
| Ruff, P | 1 |
| Chasen, MR | 1 |
| Long, JE | 1 |
| van Rensburg, CE | 1 |
| Falkson, CI | 1 |
| Falkson, G | 1 |
2 trials available for clofazimine and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi | 1998 |
A phase II evaluation of clofazimine plus doxorubicin in advanced, unresectable primary hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 1999 |
3 other studies available for clofazimine and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Protein-beta; Cell Line; Cell Transformat | 2021 |
Regression of Novikoff rat hepatocellular carcinoma following locoregional administration of a novel formulation of clofazimine in lipiodol.
Topics: Administration, Oral; Animals; Apoptosis; Azo Compounds; Carcinoma, Hepatocellular; Cell Division; C | 2004 |
HLA expression in hepatocellular carcinoma cell lines.
Topics: Butyrates; Butyric Acid; Carcinoma, Hepatocellular; Clofazimine; Enzyme-Linked Immunosorbent Assay; | 1994 |